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Objective
The polymerase DNA gamma (POLG1) gene has major
role in the biogenesis of mitochondrial DNA (mtDNA).
POLG1 gene alterations may result in secondary multiple
deletions in the mtDNA. Mutations in the POLG1 gene
have been described with wide range of mitochondrial
diseases, such as PEO, Alpers syndrome, and Parkinson-
ism. Until now seven POLG1 mutations (L304R, A467T,
G588D, Q879H, T885S, E1143G and Q1236H) have
pharmacogenetic significance to associate with valproic
acid (VPA) induced liver toxicity. VPA is an anticonvul-
sant and mood-stabilizing drug using in the treatment of
epilepsy, bipolar disorder.
Patients and methods
We have investigated 61 patients with mitochondrial
disease (male: 18, female: 43, mean age: 39±24 years) har-
bouring multiple mtDNA deletions in their muscle tissue.
The mtDNA deletions were screened with long PCR. The
total coding regions of the POLG1 gene (23 exons) were
sequenced by Sanger method (ABI Prism 3500).
Results
Three mutations (A467T, Q1143G, Q1236H) of the six
VPA toxicity associated mutations have been found in
18 cases (29, 5%). The most frequently pathogenic POLG1
mutation in Caucasian population is the A467T (c.1399
G>A in exon 7) was found in one 4-year-old boy in het-
erozygous form. The sister of this child had VPA induced
fatal hepatotoxicity. The E1143G (c.3428 A>G in exon 21)
polymorfism was detected in 7 cases (male: 2, female: 5,
mean age: 44±19, 68) in heterozygous form. We have
found in 10 patients (male: 2, female: 8, mean age: 42±23,
75) the Q1236H (c.3708 G>T in exon 23) substitution in
2 cases homozygous, and in 8 cases heterozygous form.
Conclusion
In mitochondrial disorders there is a high prevalence
of VPA toxicity predicting genomic alterations. It has a
major role in the disease management of these patients.
In such cases before VPA treatment genotyping should
be recommended to prevent the fatal hepatotoxicity.
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